Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Pain
Published in: Molecular Pain 1/2010

Open Access 01-12-2010 | Research

Effects of ranolazine on wild-type and mutant hNav1.7 channels and on DRG neuron excitability

Authors: Mark Estacion, Stephen G Waxman, Sulayman D Dib-Hajj

Published in: Molecular Pain | Issue 1/2010

Login to get access

Abstract

Background

A direct role of sodium channels in pain has recently been confirmed by establishing a monogenic link between SCN9A, the gene which encodes sodium channel Nav1.7, and pain disorders in humans, with gain-of-function mutations causing severe pain syndromes, and loss-of-function mutations causing congenital indifference to pain. Expression of sodium channel Nav1.8 in DRG neurons has also been shown to be essential for the manifestation of mutant Nav1.7-induced neuronal hyperexcitability. These findings have confirmed key roles of Nav1.7 and Nav1.8 in pain and identify these channels as novel targets for pain therapeutic development. Ranolazine preferentially blocks cardiac late sodium currents at concentrations that do not significantly reduce peak sodium current. Ranolazine also blocks wild-type Nav1.7 and Nav1.8 channels in a use-dependent manner. However, ranolazine's effects on gain-of-function mutations of Nav1.7 and on DRG neuron excitability have not been investigated. We used voltage- and current-clamp recordings to evaluate the hypothesis that ranolazine may be effective in regulating Nav1.7-induced DRG neuron hyperexcitability.

Results

We show that ranolazine produces comparable block of peak and ramp currents of wild-type Nav1.7 and mutant Nav1.7 channels linked to Inherited Erythromelalgia and Paroxysmal Extreme Pain Disorder. We also show that ranolazine, at a clinically-relevant concentration, blocks high-frequency firing of DRG neurons expressing wild-type but not mutant channels.

Conclusions

Our data suggest that ranalozine can attenuate hyperexcitability of DRG neurons over-expressing wild-type Nav1.7 channels, as occurs in acquired neuropathic and inflammatory pain, and thus merits further study as an alternative to existing non-selective sodium channel blockers.
Appendix
Available only for authorised users
Literature
1.
Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, et al.: Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007,132(3):237–251. 10.1016/j.pain.2007.08.033PubMedCrossRef
2.
Dib-Hajj SD, Cummins TR, Black JA, Waxman SG: From genes to pain: Na v 1.7 and human pain disorders. Trends Neurosci 2007,30(11):555–563. 10.1016/j.tins.2007.08.004PubMedCrossRef
3.
Waxman SG: Channel, neuronal and clinical function in sodium channelopathies: from genotype to phenotype. Nat Neurosci 2007,10(4):405–409. 10.1038/nn1857PubMedCrossRef
4.
Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, Thomas G: Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004,110(8):904–910. 10.1161/01.CIR.0000139333.83620.5DPubMedCentralPubMedCrossRef
5.
Belardinelli L, Shryock JC, Fraser H: Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 2006,92(Suppl 4):iv6-iv14. 10.1136/hrt.2005.078790PubMedCentralPubMed
6.
Fredj S, Sampson KJ, Liu H, Kass RS: Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol 2006.
7.
Undrovinas AI, Belardinelli L, Undrovinas NA, Sabbah HN: Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol 2006,17(Suppl 1):S169–177. 10.1111/j.1540-8167.2006.00401.xPubMedCentralPubMedCrossRef
8.
Wang GK, Calderon J, Wang SY: State- and use-dependent block of muscle Nav1.4 and neuronal Nav1.7 voltage-gated Na+ channel isoforms by ranolazine. Mol Pharmacol 2008,73(3):940–948. 10.1124/mol.107.041541PubMedCentralPubMedCrossRef
9.
Rajamani S, Shryock JC, Belardinelli L: Block of tetrodotoxin-sensitive, Na V 1.7 and tetrodotoxin-resistant, Na V 1.8, Na + channels by ranolazine. Channels 2008,2(6):449–460. 10.4161/chan.2.6.7362PubMedCrossRef
10.
Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C: Atrium-Selective Sodium Channel Block as a Strategy for Suppression of Atrial Fibrillation. Differences in Sodium Channel Inactivation Between Atria and Ventricles and the Role of Ranolazine. Circulation 2007.
11.
Black JA, Liu S, Tanaka M, Cummins TR, Waxman SG: Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain. Pain 2004,108(3):237–247. 10.1016/j.pain.2003.12.035PubMedCrossRef
12.
Black JA, Nikolajsen L, Kroner K, Jensen TS, Waxman SG: Multiple sodium channel isoforms and mitogen-activated protein kinases are present in painful human neuromas. Ann Neurol 2008,64(6):644–653. 10.1002/ana.21527PubMedCrossRef
13.
Cummins TR, Howe JR, Waxman SG: Slow closed-state inactivation: a novel mechanism underlying ramp currents in cells expressing the hNE/PN1 sodium channel. J Neurosci 1998,18(23):9607–9619.PubMed
14.
Dib-Hajj SD, Rush AM, Cummins TR, Hisama FM, Novella S, Tyrrell L, Marshall L, Waxman SG: Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain 2005,128(Pt 8):1847–1854. 10.1093/brain/awh514PubMedCrossRef
15.
Estacion M, Dib-Hajj SD, Benke PJ, Te Morsche RH, Eastman EM, Macala LJ, Drenth JP, Waxman SG: Na v 1.7 gain-of-function mutations as a continuum: A1632E displays physiological changes associated with erythromelalgia and paroxysmal extreme pain disorder mutations and produces symptoms of both disorders. J Neurosci 2008,28(43):11079–11088. 10.1523/JNEUROSCI.3443-08.2008PubMedCrossRef
16.
Han C, Dib-Hajj SD, Lin Z, Li Y, Eastman EM, Tyrrell L, Cao X, Yang Y, Waxman SG: Early- and late-onset inherited erythromelalgia: genotype-phenotype correlation. Brain 2009,132(7):1711–1722. 10.1093/brain/awp078PubMedCrossRef
17.
Harty TP, Dib-Hajj SD, Tyrrell L, Blackman R, Hisama FM, Rose JB, Waxman SG: Na V 1.7 mutant A863P in erythromelalgia: effects of altered activation and steady-state inactivation on excitability of nociceptive dorsal root ganglion neurons. J Neurosci 2006,26(48):12566–12575. 10.1523/JNEUROSCI.3424-06.2006PubMedCrossRef
18.
Rush AM, Dib-Hajj SD, Liu S, Cummins TR, Black JA, Waxman SG: A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. Proc Natl Acad Sci USA 2006,103(21):8245–8250. 10.1073/pnas.0602813103PubMedCentralPubMedCrossRef
19.
Stamboulian S, Choi J-S, Ahn H-S, Chang Y-W, Tyrrell L, Black J, Waxman S, Dib-Hajj S: ERK1/2 phosphorylates sodium channel Nav1.7 and alters its gating properties. J Neurosci 2010,30(5):1637–1647. 10.1523/JNEUROSCI.4872-09.2010PubMedCrossRef
20.
Cummins TR, Dib-Hajj SD, Waxman SG: Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy. J Neurosci 2004,24(38):8232–8236. 10.1523/JNEUROSCI.2695-04.2004PubMedCrossRef
21.
Jarecki BW, Sheets PL, Jackson JO, Cummins TR: Paroxysmal extreme pain disorder mutations within the D3/S4-S5 linker of Nav1.7 cause moderate destabilization of fast inactivation. J Physiol 2008,586(Pt 17):4137–4153. 10.1113/jphysiol.2008.154906PubMedCentralPubMedCrossRef
22.
Cheng X, Dib-Hajj SD, Tyrrell L, Wright DE, Fischer TZ, Waxman SG: Mutations at opposite ends of the DIII/S4-S5 linker of sodium channel Na v 1.7 produce distinct pain disorders. Mol Pain 2010, 6: 24. 10.1186/1744-8069-6-24PubMedCentralPubMedCrossRef
23.
Herzog RI, Cummins TR, Ghassemi F, Dib-Hajj SD, Waxman SG: Distinct repriming and closed-state inactivation kinetics of Nav1.6 and Nav1.7 sodium channels in mouse spinal sensory neurons. J Physiol (Lond) 2003,551(Pt 3):741–750. 10.1113/jphysiol.2003.047357CrossRef
24.
Choi JS, Dib-Hajj SD, Waxman S: Differential slow inactivation and use-dependent inhibition of Nav1.8 channels contribute to distinct firing properties in IB4+ and IB4- DRG neurons. J Neurophysiol 2007,97(2):1258–1265. 10.1152/jn.01033.2006PubMedCrossRef
25.
Fang X, Djouhri L, McMullan S, Berry C, Waxman SG, Okuse K, Lawson SN: Intense isolectin-B4 binding in rat dorsal root ganglion neurons distinguishes C-fiber nociceptors with broad action potentials and high Nav1.9 expression. J Neurosci 2006,26(27):7281–7292. 10.1523/JNEUROSCI.1072-06.2006PubMedCrossRef
26.
Rush AM, Cummins TR, Waxman SG: Multiple sodium channels and their roles in electrogenesis within dorsal root ganglion neurons. J Physiol (Lond) 2007,579(Pt 1):1–14. 10.1113/jphysiol.2006.121483CrossRef
27.
Dib-Hajj SD, Estacion M, Jarecki BW, Tyrrell L, Fischer TZ, Lawden M, Cummins TR, Waxman SG: Paroxysmal extreme pain disorder M1627K mutation in human Nav1.7 renders DRG neurons hyperexcitable. Mol Pain 2008, 4: 37. 10.1186/1744-8069-4-37PubMedCentralPubMedCrossRef
28.
Rajamani S, Shryock JC, Belardinelli L: Rapid kinetic interactions of ranolazine with HERG K+ current. J Cardiovasc Pharmacol 2008,51(6):581–589. 10.1097/FJC.0b013e3181799690PubMedCrossRef
29.
Gould HJ, Garrett C, Donahue RR, Paul D, Diamond I, Taylor BK: Ranolazine attenuates behavioral signs of neuropathic pain. Behav Pharmacol 2009, in press. PMID: 19773645
30.
Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, Molhoek P, Verheugt FW, Gersh BJ, McCabe CH, et al.: Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007,116(15):1647–1652. 10.1161/CIRCULATIONAHA.107.724880PubMedCrossRef
31.
Yang Y, Wang Y, Li S, Xu Z, Li H, Ma L, Fan J, Bu D, Liu B, Fan Z, et al.: Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet 2004,41(3):171–174. 10.1136/jmg.2003.012153PubMedCentralPubMedCrossRef
32.
Fertleman CR, Baker MD, Parker KA, Moffatt S, Elmslie FV, Abrahamsen B, Ostman J, Klugbauer N, Wood JN, Gardiner RM, et al.: SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 2006,52(5):767–774. 10.1016/j.neuron.2006.10.006PubMedCrossRef
33.
Han C, Rush AM, Dib-Hajj SD, Li S, Xu Z, Wang Y, Tyrrell L, Wang X, Yang Y, Waxman SG: Sporadic onset of erythermalgia: a gain-of-function mutation in Nav1.7. Ann Neurol 2006, 59: 553–558. 10.1002/ana.20776PubMedCrossRef
34.
Lampert A, Dib-Hajj SD, Tyrrell L, Waxman SG: Size matters: Erythromelalgia mutation S241T in Nav1.7 alters channel gating. J Biol Chem 2006,281(47):36029–36035. 10.1074/jbc.M607637200PubMedCrossRef
35.
Dib-Hajj SD, Choi JS, Macala LJ, Tyrrell L, Black JA, Cummins TR, Waxman SG: Transfection of rat or mouse neurons by biolistics or electroporation. Nat Protoc 2009,4(8):1118–1126. 10.1038/nprot.2009.90PubMedCrossRef
Metadata
Title
Effects of ranolazine on wild-type and mutant hNav1.7 channels and on DRG neuron excitability
Authors
Mark Estacion
Stephen G Waxman
Sulayman D Dib-Hajj
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Pain / Issue 1/2010
Electronic ISSN: 1744-8069
DOI
https://doi.org/10.1186/1744-8069-6-35

Other articles of this Issue 1/2010

Molecular Pain 1/2010 Go to the issue

Research

Dissociation of μ- and δ-opioid inhibition of glutamatergic synaptic transmission in superficial dorsal horn

Research

Expression of leukotriene receptors in the rat dorsal root ganglion and the effects on pain behaviors

Research

KATP channel subunits in rat dorsal root ganglia: alterations by painful axotomy

Research

Quantitative automated microscopy (QuAM) elucidates growth factor specific signalling in pain sensitization

Research

Gi- and Gq-coupled ADP (P2Y) receptors act in opposition to modulate nociceptive signaling and inflammatory pain behavior

Research

Inflammatory nociception diminishes dopamine release and increases dopamine D2 receptor mRNA in the rat's insular cortex